Prospects of using interferon inducers of the double stranded RNA type for the treatment of viral and bacterial infections

O. Radaeva, A. V. Taganov, E. A. Rogozhina
{"title":"Prospects of using interferon inducers of the double stranded RNA type for the treatment of viral and bacterial infections","authors":"O. Radaeva, A. V. Taganov, E. A. Rogozhina","doi":"10.32364/2587-6821-2022-6-11-643-649","DOIUrl":null,"url":null,"abstract":"The article highlights the role of the interferon system in the host defense against infections, primarily those caused by viral agents. The authors explain the effect of double stranded RNA (dsRNA)-based products used as interferon inducers (II) from a pathogenesis standpoint. The key advantage of interferon inducers is a broad spectrum of antiviral activity based on immunomodulating and secondary etiotropic effects. The addition of the so-called early-type II (the production of interferon occurs 2 — 6 hours after administration) to the treatment schemes promotes a timely and adequate immune response and helps to achieve a therapeutic effect. Despite a long-standing interest in the natural dsRNA, the imperfection of the described methods of its synthesis provided the impetus for finding and developing techniques aimed at creating an efficient and safe product. A novel technology of sodium ribonucleinate production enabled to receive an active bacterial endotoxin-free pharmaceutical substance and to minimize the concentration of related impurities which considerably increased the product safety. The innovative solutions underpinning the production of an advanced interferon inducer of the double stranded RNA type will significantly expand the potential applications of interferon therapy. KEYWORDS: antivirals, interferons, interferon inducers, Radamin Viro, sodium ribonucleinate. FOR CITATION: Radaeva O.A., Taganov A.V., Rogozhina E.A. Prospects of using interferon inducers of the double stranded RNA type for the treatment of viral and bacterial infections. Russian Medical Inquiry. 2022;6(11):643–649 (in Russ.). DOI: 10.32364/2587-6821- 2022-6-11-643-649.","PeriodicalId":21378,"journal":{"name":"Russian Medical Inquiry","volume":"123 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Medical Inquiry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2587-6821-2022-6-11-643-649","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The article highlights the role of the interferon system in the host defense against infections, primarily those caused by viral agents. The authors explain the effect of double stranded RNA (dsRNA)-based products used as interferon inducers (II) from a pathogenesis standpoint. The key advantage of interferon inducers is a broad spectrum of antiviral activity based on immunomodulating and secondary etiotropic effects. The addition of the so-called early-type II (the production of interferon occurs 2 — 6 hours after administration) to the treatment schemes promotes a timely and adequate immune response and helps to achieve a therapeutic effect. Despite a long-standing interest in the natural dsRNA, the imperfection of the described methods of its synthesis provided the impetus for finding and developing techniques aimed at creating an efficient and safe product. A novel technology of sodium ribonucleinate production enabled to receive an active bacterial endotoxin-free pharmaceutical substance and to minimize the concentration of related impurities which considerably increased the product safety. The innovative solutions underpinning the production of an advanced interferon inducer of the double stranded RNA type will significantly expand the potential applications of interferon therapy. KEYWORDS: antivirals, interferons, interferon inducers, Radamin Viro, sodium ribonucleinate. FOR CITATION: Radaeva O.A., Taganov A.V., Rogozhina E.A. Prospects of using interferon inducers of the double stranded RNA type for the treatment of viral and bacterial infections. Russian Medical Inquiry. 2022;6(11):643–649 (in Russ.). DOI: 10.32364/2587-6821- 2022-6-11-643-649.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
双链RNA型干扰素诱导剂治疗病毒和细菌感染的前景
本文强调了干扰素系统在宿主防御感染中的作用,主要是那些由病毒制剂引起的感染。作者从发病机制的角度解释了以双链RNA (dsRNA)为基础的产品用作干扰素诱导剂(II)的作用。干扰素诱导剂的主要优势是基于免疫调节和继发性致病因作用的广谱抗病毒活性。在治疗方案中加入所谓的早期II型(干扰素的产生发生在给药后2 - 6小时),可促进及时和充分的免疫反应,并有助于达到治疗效果。尽管人们长期对天然dsRNA感兴趣,但所描述的合成方法的不完善为寻找和开发旨在创造高效和安全产品的技术提供了动力。一种新的核糖核酸酸钠生产技术能够获得活性细菌无内毒素药物物质,并将相关杂质的浓度降至最低,从而大大提高了产品的安全性。创新的解决方案支持生产先进的双链RNA型干扰素诱导剂,将显著扩大干扰素治疗的潜在应用。关键词:抗病毒药物,干扰素,干扰素诱导剂,Radamin Viro,核糖核酸酸钠引文:Radaeva o.a., Taganov a.v., Rogozhina E.A.使用双链RNA型干扰素诱导剂治疗病毒和细菌感染的前景。俄罗斯医学调查,2022;6(11):643-649。Doi: 10.32364/2587-6821- 2022-6-11-643-649。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
期刊最新文献
Metabolic neuroprotection in patient with chronic heart failure: a case report and study results Poor patient adherence to medication treatments and solutions for overcoming compliance barriers as illustrated by antiplatelet therapy Issues concerning early diagnosis and timely correction of respiratory disorders in amyotrophic lateral sclerosis (literature review) Takayasu's arteritis after coronavirus disease in young woman: case report IBS phenotype associated with obesity and overweight: treatment tactics for patient-centered management
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1